Thr354

Site Information
HLGPHRstPEsRAAV SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 451669
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	electrophoretic mobility shift ( 12 , 25 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 ) , microscopy-colocalization with upstream kinase ( 12 ) , mutation of modification site ( 12 , 25 ) , phospho-antibody ( 12 ) , western blotting ( 12 )
Disease tissue studied:	lung cancer ( 1 , 2 , 3 , 4 , 5 , 6 , 7 ) , non-small cell lung cancer ( 2 , 3 , 4 , 6 , 7 , 8 , 9 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 , 5 , 6 , 7 , 9 ) , non-small cell large cell lung carcinoma ( 3 , 6 ) , non-small cell squamous cell lung carcinoma ( 5 ) , small-cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:	293 (epithelial) ( 15 , 16 , 17 , 18 ) , A549 (pulmonary) ( 2 ) , Cal-12T (pulmonary) ( 7 ) , Calu-3 (pulmonary) ( 4 ) , CHO (fibroblast) [CDK5 (human)] ( 25 ) , CHO (fibroblast) [PSEN1 (human)] ( 25 ) , DMS53 (pulmonary) ( 1 ) , HCC15 (pulmonary) ( 5 ) , HCC44 (pulmonary) ( 7 ) , HCC78 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 4 ) , HEK293T (epithelial) [DYRK1A (human), transfection] ( 12 ) , HEK293T (epithelial) ( 12 ) , HeLa (cervical) ( 11 , 13 , 14 , 21 , 22 , 23 , 24 ) , Jurkat (T lymphocyte) ( 10 , 19 , 20 ) , LOU-NH91 (squamous) ( 5 ) , lung ( 1 , 2 , 3 , 4 , 5 , 6 , 7 ) , NCI-H1299 (pulmonary) ( 3 ) , NCI-H1355 (pulmonary) ( 2 ) , NCI-H1437 (pulmonary) ( 7 ) , NCI-H1650 (pulmonary) ( 4 ) , NCI-H1666 (pulmonary) ( 7 ) , NCI-H1703 (squamous) ( 5 ) , NCI-H1734 (pulmonary) ( 3 ) , NCI-H1781 (pulmonary) ( 6 ) , NCI-H1792 (pulmonary) ( 2 ) , NCI-H1944 (pulmonary) ( 3 ) , NCI-H1975 (pulmonary) ( 4 ) , NCI-H2073 (pulmonary) ( 5 ) , NCI-H2106 (pulmonary) ( 4 ) , NCI-H2228 (pulmonary) ( 6 , 9 ) , NCI-H23 (pulmonary) ( 2 ) , NCI-H2342 (pulmonary) ( 5 ) , NCI-H2405 (pulmonary) ( 7 ) , NCI-H3122 (pulmonary) ( 6 , 8 ) , NCI-H358 (pulmonary) ( 3 ) , NCI-H441 (pulmonary) ( 2 ) , NCI-H446 (pulmonary) ( 1 ) , NCI-H460 (pulmonary) ( 3 ) , NCI-H526 (pulmonary) ( 1 ) , NCI-H661 (pulmonary) ( 6 ) , NCI-H69 (pulmonary) ( 1 ) , NCI-H82 (pulmonary) ( 1 )

Upstream Regulation
Putative in vivo kinases:	CDK5 (human) ( 25 ) , DYRK1A (mouse) ( 12 )
Kinases, in vitro:	CDK5 (human) ( 25 )
Treatments:	peptide_antagonist ( 12 )

Downstream Regulation
Effects of modification on PSEN1:	enzymatic activity, induced ( 12 ) , protein stabilization ( 12 , 25 )

References
1	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
2	Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
3	Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
4	Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
5	Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
6	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
7	Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
8	Rikova K (2013) CST Curation Set: 18860; Year: 2012; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
9	Rikova K (2013) CST Curation Set: 18859; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pT Curated Info
10	Zhou J (2011) CST Curation Set: 12497; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info
11	Guo A (2011) CST Curation Set: 11453; Year: 2011; Biosample/Treatment: cell line, HeLa/nocodazole &'\|\|' pervanadate; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (STP) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (STP) Immunoaffinity Beads Cat#: 5756 Curated Info
12	Ryu YS, et al. (2010) Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease. J Neurochem 115, 574-84 20456003 Curated Info
13	Zhou J (2010) CST Curation Set: 10691; Year: 2010; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (STP) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (STP) Immunoaffinity Beads Cat#: 5756 Curated Info
14	Zhou J (2010) CST Curation Set: 10690; Year: 2010; Biosample/Treatment: cell line, HeLa/untreated; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (STP) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (STP) Immunoaffinity Beads Cat#: 5756 Curated Info
15	Guo A (2010) CST Curation Set: 9972; Year: 2010; Biosample/Treatment: cell line, 293/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
16	Guo A (2010) CST Curation Set: 9969; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
17	Guo A (2010) CST Curation Set: 9973; Year: 2010; Biosample/Treatment: cell line, 293/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
18	Guo A (2010) CST Curation Set: 9971; Year: 2010; Biosample/Treatment: cell line, 293/mTOR inhibitor; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Millipore 05-368 Curated Info
19	Possemato A (2008) CST Curation Set: 5273; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
20	Possemato A (2008) CST Curation Set: 5274; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
21	Moritz A (2008) CST Curation Set: 5060; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
22	Moritz A (2008) CST Curation Set: 5061; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
23	Moritz A (2008) CST Curation Set: 5070; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
24	Moritz A (2008) CST Curation Set: 5071; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P , PTMScan(R) PLK Binding Motif (SpTP) Immunoaffinity Beads Cat#: 1995 Curated Info
25	Lau KF, et al. (2002) Cyclin-dependent kinase-5/p35 phosphorylates Presenilin 1 to regulate carboxy-terminal fragment stability. Mol Cell Neurosci 20, 13-20 12056836 Curated Info